🚀 VC round data is live in beta, check it out!
Tevogen Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Tevogen Bio and similar public comparables like AN2 Therapeutics, Tempest Therapeutics, Rein Therapeutics, Werewolf Therapeutics and more.
Tevogen Bio Overview
About Tevogen Bio
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Founded
2021
HQ
Employees
18
Website
Sectors
Financials (LTM)
EV
$46M
Tevogen Bio Financials
Tevogen Bio reported last 12-month revenue of —.
In the same LTM period, Tevogen Bio generated had net loss of ($32M).
Revenue (LTM)
Tevogen Bio P&L
In the most recent fiscal year, Tevogen Bio reported revenue of — and EBITDA of ($13M).
Tevogen Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($13M) | XXX | XXX | XXX |
| Net Profit | ($32M) | XXX | ($14M) | XXX | XXX | XXX |
| Net Debt | — | — | $1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Tevogen Bio Stock Performance
Tevogen Bio has current market cap of $30M, and enterprise value of $46M.
Market Cap Evolution
Tevogen Bio's stock price is $7.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $46M | $30M | 0.0% | XXX | XXX | XXX | $-3.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTevogen Bio Valuation Multiples
Tevogen Bio trades at (3.5x) EV/EBITDA.
Tevogen Bio Financial Valuation Multiples
As of March 18, 2026, Tevogen Bio has market cap of $30M and EV of $46M.
Equity research analysts estimate Tevogen Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tevogen Bio has a P/E ratio of (0.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $30M | XXX | $30M | XXX | XXX | XXX |
| EV (current) | $46M | XXX | $46M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.5x) | XXX | XXX | XXX |
| EV/EBIT | (1.4x) | XXX | (0.9x) | XXX | XXX | XXX |
| P/E | (0.9x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Tevogen Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Tevogen Bio Margins & Growth Rates
Tevogen Bio's revenue in the last fiscal year grew by —.
Tevogen Bio's revenue per employee in the last FY averaged $0.0M.
Tevogen Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (7063%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Tevogen Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| AN2 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempest Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rein Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Werewolf Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lantern Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tevogen Bio M&A Activity
Tevogen Bio acquired XXX companies to date.
Last acquisition by Tevogen Bio was on XXXXXXXX, XXXXX. Tevogen Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Tevogen Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTevogen Bio Investment Activity
Tevogen Bio invested in XXX companies to date.
Tevogen Bio made its latest investment on XXXXXXXX, XXXXX. Tevogen Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Tevogen Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Tevogen Bio
| When was Tevogen Bio founded? | Tevogen Bio was founded in 2021. |
| Where is Tevogen Bio headquartered? | Tevogen Bio is headquartered in United States. |
| How many employees does Tevogen Bio have? | As of today, Tevogen Bio has over 18 employees. |
| Who is the CEO of Tevogen Bio? | Tevogen Bio's CEO is Ryan Saadi. |
| Is Tevogen Bio publicly listed? | Yes, Tevogen Bio is a public company listed on Nasdaq. |
| What is the stock symbol of Tevogen Bio? | Tevogen Bio trades under TVGN ticker. |
| When did Tevogen Bio go public? | Tevogen Bio went public in 2024. |
| Who are competitors of Tevogen Bio? | Tevogen Bio main competitors are AN2 Therapeutics, Tempest Therapeutics, Rein Therapeutics, Werewolf Therapeutics. |
| What is the current market cap of Tevogen Bio? | Tevogen Bio's current market cap is $30M. |
| Is Tevogen Bio profitable? | No, Tevogen Bio is not profitable. |
| What is the current net income of Tevogen Bio? | Tevogen Bio's last 12 months net income is ($32M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.